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ABSTRACT 
 
OBJECTIVE – To test whether the implementation of elements of the Chronic Care Model 
(CCM) via a specially trained practice nurse leads to an improved cardiovascular risk profile 
among type 2 diabetes patients. 
 
RESEARCH DESIGN AND METHODS – This cluster randomized controlled trial with 
primary care physicians as unit of randomization was conducted in the German part of 
Switzerland. 326 type 2 diabetes patients (age >18 years, at least one HbA1c level of ≥7.0% 
[53 mmol/mol] in preceding year) from 30 primary care practices participated. The 
intervention included implementation of CCM elements and involvement of practice nurses in 
the care of type 2 diabetes patients. Primary outcome was glycosylated hemoglobin (HbA1c) 
levels. The secondary outcomes were blood pressure (BP), LDL-cholesterol, accordance to 
CCM (assessed by PACIC) and quality of life (assessed by SF-36). 
 
RESULTS – After 1 year HbA1c decreased significantly in both groups with no significant 
difference between groups (-0.05% [-0.60 mmol/mol]; p=0.708). Among intervention group 
patients, systolic BP (-3.63; p<0.001), diastolic BP (-4.01; p=0.050), LDL-cholesterol (-0.21; 
p=0.033) and PACIC subscores (p<0.001 to p=0.048) significantly improved compared to 
control group patients. No differences between groups were shown in the SF-36 subscales. 
 
CONCLUSIONS – A chronic care approach according to the CCM and involving practice 
nurses in diabetes care improved the cardiovascular risk profile and is experienced by patients 
as a better structured care. Our study showed that care according to the CCM can be 
implemented even in small primary care practices which still represent the usual structure in 
most European health care systems. 
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 TRIAL REGISTRATION: Current controlled trials: ISRCTN05947538 
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Chronic diseases and multimorbidity show an increasing prevalence in most industrialized 
countries, also in Switzerland (1). Among these chronic diseases, diabetes is one of the most 
prevalent ones (2). The Chronic Care Model (CCM) has been developed as evidence based 
approach for the care of chronically ill patients. A central element of the CCM is the team 
centered care approach which facilitates and produces effective interactions between 
proactive primary care practice teams and empowered patients with the aim to improve 
processes and outcomes in chronic illnesses(3, 4).  
In contrast to the United States, experiences in European countries with the CCM approach 
are rare. Many European health care systems, as for example in Germany, Austria, 
Switzerland, France, Italy and Spain are physician centered and do not involve practice nurses 
or other non-physician professions in care. Health politicians in these countries are very 
interested in team based approaches, especially in the care for chronically ills, since on the 
one hand the number of these patients is increasing and on the other hand a shortage of 
primary care physicians (PCPs) exists in most of these countries (5). 
Regarding the care for diabetes patients, the optimal cardiovascular risk profile is one of the 
most important targets for health expectancy and quality of life (6). The aim of this study was 
to investigate if a team based approach according to the CCM which included the 
involvement of a practice nurse in the care for type 2 diabetes patients results in an improved 
cardiovascular risk profile after one year, namely glycosylated hemoglobin (HbA1c), blood 
pressure (BP) and LDL-cholesterol. Additionally, we examined if the intervention resulted in 
an improved quality of life of the patients and improved patients’ perspective of the provided 
care.  
 
RESEARCH DESIGN AND METHODS 
This study was a cluster randomized controlled trial with PCPs as unit of randomization. 
Detailed information about design and methods (7) and the patients’ baseline characteristics 
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(8) of the study was published previously. The study protocol has been approved by the ethics 
committee of the Kanton Zurich and received an unrestricted positive vote on 25.01.2010. 
 
Recruitment of participants 
Eligible criteria for PCPs were that they participated in routine primary care of unselected 
patients. If they were working in a non-single-handed practice it was required that patients 
were clearly allocated to individual PCPs. About 800 randomly selected PCPs from the 
Eastern part of Switzerland were invited to an information meeting on the study. Additionally, 
the project was presented in several quality circle meetings in PCPs’ networks.  
Eligible patients were identified through the PCPs registry based on laboratory results and 
received an invitation letter by the PCPs with information about the study. Patients were 
included in consecutive order of attendance in the practice, regardless the reason for the 
encounter. The inclusion criteria were adulthood (age >18 years), diagnosis of type 2 diabetes 
according to international diagnostic criteria (9) and at least one HbA1c level of ≥7.0% (53 
mmol/mol) measured within the preceding year. The latter criterion was formulated because 
the aim of the study was to reduce HbA1c values by 0.5% points considering the current 
recommendations in guidelines (HbA1c = 6.5% [48 mmol/mol]) at study onset (10). 
Exclusion criteria were insufficient language skills to read and understand informed consent, 
patient information and the questionnaires, practice contact for emergencies only (i.e. no 
continuous patient-doctor relationship) and a life expectancy less than six months.  
 
Intervention 
The intervention aimed at providing team care according to the CCM. To perform CCM based 
care a team approach involving the practice nurse is required. Usual care in Switzerland is 
focused on the PCP and the PCP-patient relationship, based on Good Clinical Practice. Like 
in most European countries, practice nurses in Switzerland are currently only marginally 
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involved in the care for patients and their education is less focused on medical issues but 
addresses mainly administrative matters. We established the intervention based on the results 
of a qualitative pre-study concerning the implementation of CCM elements and the 
involvement of practice nurses (11) and on preliminary results of a systematic review 
conducted by our research group assessing effective interventions in primary care to improve 
care for diabetes patients (12).  
Intervention on cluster level (provider of health care) 
Practice nurses of the intervention group were trained right after randomization in a 6 days 
educational course "Treatment of long term patients – module diabetes", organized by the 
union of Swiss practice nurses (13). The course provided medical knowledge for the treatment 
of diabetes patients, general communication skills and it empowered practice nurses for their 
role in a team providing structured care for chronically ills. The practice nurses also learned 
how to perform visits and follow-up consultations by means of a monitoring tool developed 
for the study (described below) (14). 
In addition, PCPs and practice nurses from the intervention group participated in two 4-hours 
interactive workshops. The first workshop was scheduled right after randomization and 
addressed the implementation of the team approach in practice and evidenced-based therapy 
of diabetes. The second workshop took part after 6 study months and covered professional 
exchange between practice nurses and PCPs regarding implementation experience and 
management of cardiovascular risk factors.  
Intervention on practice level (patients) 
The intervention on practice level contained that practice nurses were involved in the care of 
type 2 diabetes patients. Practice nurses planned independent consultations with patients. The 
monitoring tool guided them through the consultations, provided the opportunity to record 
relevant parameters and assistance for self-management support in order to reinforce the 
patient in selecting appropriate, concrete behavioral goals, in developing plans for reaching 
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those goals and in evaluating the progress and adequacy of those plans. The monitoring tool 
addressed clinical parameters (e.g. HbA1c, BP, LDL-cholesterol), examinations (e.g. food 
control, neurological tests, eye examination), adherence to prescribed drugs, self-care goals 
and other recommendations. The clinical aim of the tool was to ensure that treatment 
recommendations were followed. The assessed parameters were classified regarding their 
clinical urgency and importance into a traffic light scheme (green, amber, red) and the 
practice nurses forwarded the tool to the PCPs. So the PCPs obtained an immediate overview 
on the current situation of the patients. We recommended practice nurse consultations every 4 
months but frequency could be adapted according to the clinical situation of the patient (14). 
Overall, the intervention included the implementation of the CCM elements organization of 
health care and delivery system design (involvement of practice nurse), clinical information 
systems (use of CARAT-monitoring tool), decision support (guideline based instructions on 
the tool, availability of diabetes specialist at the University Hospital Zurich) and self-
management support (provided by the practice nurse). More detailed information is provided 
in the study protocol (7). 
 
Outcome measures 
The primary study outcome was the HbA1c level. Secondary clinical outcomes were the 
cardiovascular risk factors systolic and diastolic BP and LDL-cholesterol. Clinical parameters 
were assessed by the practice team using point-of-care laboratory analysis and/or external 
laboratories. Patient-reported secondary outcomes were accordance to the CCM from 
patients’ perspective measured by the Patient Assessment of Chronic Illness Care 
questionnaire (PACIC) (15, 16) and generic health-related quality of life assessed by the SF-
36 (17).  
 
Sample size 
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We aimed at inducing a reduction of 0.5% points in the HbA1c for the intervention group 
patients. Since no epidemiological data regarding HbA1c from the Swiss primary care setting 
was available at the time of study protocol development, we assumed based on previous 
German data (18) and on our inclusion criteria (HbA1c ≥7.0% [53 mmol/mol]) a mean 
HbA1c of 7.7% (61 mmol/mol) at baseline assessment time. In accordance to data from the 
"Diabetes in Germany" (DIG)-study (19) and the ACCORD trial (20) we assumed an SD of 
1.2% (13 mmol/mol) and based on our previous studies and on data available at the website of 
the University of Aberdeen (21) an intraclass correlation coefficient of 0.04 for the primary 
outcome HbA1c. We aimed at 80% power; the significance level was set to 0.05. We 
performed the sample size calculation with the Cluster Randomization Sample Size Calculator 
version 1.02 of the University of Aberdeen. Based on our assumptions and definitions the 
sample size calculation resulted in the inclusion of 12 patients and 11 practices in each arm. 
Considering a higher drop-out rate in cluster randomized trials since the drop-out of one 
cluster leads to the loss of all patients in a cluster, we assumed a drop-out rate of 20%, 
resulting in 14 practices in each arm and 28 practices including 12 patients in total (22-24).  
 
Randomization 
The PCPs who agreed to participate in the study were alphabetically ordered by their family 
names in a list with numbers from 1 to 30. An independent research assistant who was not 
involved in the study and blind to the identity of the PCPs randomly allocated by statistical 
computer software SPSS (version 18.0) 15 letters A and 15 letters B to numbers 1 to 30 and to 
the corresponding PCPs, respectively. The assignment of the letters A and B to either 
intervention or control group was randomly conducted by a second research assistant who 
drew blinded a ticket with the letters A or B and a ticket with the group allocation intervention 
or control group from an envelope. We informed all PCPs about the group allocation after the 
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inclusion of patients and baseline assessments to minimize selection bias. We did not 
constrain cluster randomization by any stratification. 
 
Statistical methods 
Baseline characteristics of PCPs and patients according to intervention and control group are 
presented as means and standard deviations (SD) for continuous variables and frequencies and 
percentages for categorical data.  
Analyses were conducted by intention-to-treat. Missing follow-up data of patients who 
dropped-out were substituted by baseline-assessment data (last observation carried forward). 
For the primary outcome HbA1c and clinical outcomes systolic BP, diastolic BP, LDL-
cholesterol and SF-36, we analyzed mean (95% CI) differences in changes over time between 
groups using t-tests for independent samples. Intraclass correlation coefficients (ICCs) were 
calculated for the primary and clinical secondary outcomes to assess a potential clustering 
effect. To assess the independent effect of the treatment group, we additionally conducted 
multilevel regression analyses with the PCP as cluster level considering the changes over time 
in the primary and clinical secondary outcomes as predictor variables and potentially 
confounding variables as determinants (patient’s sex and age, smoking status, BMI, number 
of comorbidities, number of visits during the study year, total number of drugs, treatment of 
correspondent medication [antidiabetic therapy for HbA1c, antihypertensive therapy for blood 
pressure, lipid-lowering therapy for LDL-cholesterol], changes of correspondent medication 
during the study year). Mean differences over time of the PACIC subscales were calculated 
using the non-parametric Mann Whitney U-test, since the PACIC subscales are ordinal scaled 
and the scores were not normal distributed. The significance level was set at 0.05. Statistical 
analyses were performed using Stata 12.0 (StataCorp, 2010). 
 
RESULTS 
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A total of 30 PCPs from the German speaking part of Switzerland who recruited 326 type 2 
diabetes patients participated in the study. Recruitment of PCPs took place between 
November 2009 and February 2010, recruitment of patients and baseline assessment between 
January and April 2010. PCPs were informed about their allocated group after they finished 
patient inclusion. The intervention run from April 2010 until May 2011, and follow-up 
assessments were conducted one year after baseline assessments. Figure 1 shows the flow of 
PCPs and patients through the study. In total, 23 patients (7%) were lost to follow-up.  
PCP and patient demographic and clinical characteristics are presented in Table 1. PCPs from 
both groups were comparable, except that more control than intervention group PCPs worked 
in single handed practices.  
Table 2 shows the primary, secondary and additional clinical outcomes. At baseline, 
intervention group patients had a mean HbA1c of 7.8% (62 mmol/mol), a mean systolic BP of 
140 mmHg, a mean diastolic BP of 83 mmHg and a mean LDL-cholesterol of 2.8 mmol/l. For 
control group patients, mean HbA1c was 7.6% (59 mmol/mol), mean systolic BP 138 mmHg, 
mean diastolic BP 79 mmHg and mean LDL-cholesterol 2.5 mmol/l. At follow-up ,the 
intervention and control group did not differ significantly in the mean change over time of the 
primary outcome HbA1c, but the HbA1c improved significantly in both groups; -0.27% (-3.4 
mmol/mol; p=0.033) in the intervention and -0.22% (-2.9 mmol/mol; p= 0.002) in the control 
group. Statistically significant differences could be observed in the mean changes over time 
between the intervention and control group for the secondary clinical outcomes systolic BP, 
diastolic BP and LDL-cholesterol. In detail, systolic BP, diastolic BP and LDL-cholesterol of 
the intervention group patients improved over time, whereas the corresponding levels of the 
control group patients approximately remained. There was no evidence for a statistically 
significant clustering effect. Estimated effects based on multilevel regression analyses were of 
the same magnitude however did not reach significance level anymore for LDL-cholesterol 
changes (Supplemental Table S1).  
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Descriptive results with regard to health care utilization, further clinical outcomes and 
medications are presented comprehensively in Supplemental Table S2. Briefly, the mean 
number of visits in general practices during the last year increased in both groups (from 8.3 to 
9.6 in the intervention group, from 7.9 to 8.4 in the control group). However, the mean 
difference in change between groups was not statistically significant (1.07; p=0.155). In terms 
of changes in medications (categorized as change/no change) from baseline to follow-up, no 
significant differences could be detected regarding antidiabetic therapy (chi-square=0.03, 
p=0.862), antihypertensive therapy (chi-square=2.63, p=0.105) and lipid-lowering therapy 
(chi-square=0.57, p=0.449).  
Regarding the patient-reported secondary outcomes we found statistically significant 
differences in changes over time between intervention and control group patients in all 
PACIC subscales and the PACIC summary score showing improved levels for intervention 
group and mostly unchanged scores for control group patients at follow-up (Table 3). For all 
scores of the SF-36 subscales we did not find statistically significant differences in changes 
between the two groups over time.  
 
CONCLUSIONS 
In our study, a chronic care approach according to the CCM and involving the practice nurse 
in diabetes care improved the cardiovascular risk profile of patients with type 2 diabetes. 
Patients experienced the changes in the provided care as a better structured which is reflected 
by increased PACIC scores. Furthermore, our results showed that CCM care can be 
implemented even in inexperienced small primary care practices which still represent the 
most common situation in many European health care systems.   
After one year of intervention, the primary outcome HbA1c slightly improved in both groups 
of our study without showing a significant difference between intervention and control group. 
Several reasons might account for that. First of all, the PCPs could not be blinded; they knew 
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that they participated in a diabetes trial which might also have increased the attention towards 
the HbA1c in the control group. Furthermore, the HbA1c levels were already quite good in 
most patients at baseline, especially when taken into account that the recommendations for 
HbA1c targets changed during the study period. Current guidelines recommend less strict 
targets, especially for older patients, as most of our patients were (6, 10). Additionally, most 
of the patients in our sample were multimorbid which also might have kept PCPs away from 
very rigorous HbA1c targets. Overall, it can be concluded that the HbA1c was satisfactory in 
most patients, and only small room remained for improvement without increasing the risk of 
hypoglycemia for many of these old and multimorbid patients (25, 26). Interestingly, previous 
studies found on the one hand similar results with no significant difference of HbA1c 
decrease between the two groups (27) and on the other hand also a decline in HbA1c in the 
CCM group only (28) after the implementation of CCM elements. 
Our hypothesis that the non-significance in the HbA1c was caused by the study-participating 
effect is supported by the finding that blood pressure, which was not mentioned as being a 
primary study aim, improved significantly only in the intervention group. PCPs and practice 
nurses from the intervention group were sensitized to the management of cardiovascular risk 
factors which was topic in the educational courses and workshops. Furthermore, the 
intervention monitoring tool guided the practice nurse through a systematic monitoring of the 
BP. Nevertheless, the mean BP values at the end of the study period indicate that there is still 
room for improvement, at least for the mean systolic BP which did not fulfill current 
recommendations (6) and which was slightly higher compared to other samples (29, 30). The 
same effect occurred in the LDL-cholesterol levels. Also LDL-cholesterol was defined as a 
treatment aim in the intervention monitoring tool and was discussed as an important target in 
the interactive workshop for PCPs and practice nurses. Our data showed some medical 
treatment intensification regarding LDL-cholesterol as well as regarding BP, but whether the 
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improvements are due to the intensification or caused by an increased adherence by the 
patients can finally not be determined. 
Interestingly, according to the improvements in BP and LDL-cholesterol, patients’ 
experiences of provided care also changed. All PACIC subscales showed significantly higher 
scores over time in the intervention group. Obviously, patients experienced the changes or the 
differences in provided care which are associated with the CCM. This effect was not observed 
for control group patients, despite the improvement of their HbA1c over time.  
We could not observe significant changes over time for generic health-related quality of life 
(HRQL) which was assessed by the SF-36. The SF-36 is probably the most common HRQL 
instrument, but it is not very specific. Although the intervention resulted in improvements of 
clinical parameters and perception of the provided care, patients’ general HRQL was not 
affected. This finding emphasizes the importance of disease specific HRQL assessments to 
detect concrete changes of intervention. However, the scores of the eight SF-36 domains 
remained remarkably constant over time in both groups, the intervention and control group. 
This result supports the high test-retest reliability of the instrument in general.  
Improving diabetes care is obviously a challenging aim which may not be achieved by simple 
approaches targeting at single aims only. A recent study with similar methodology assessed 
for instance the effect of peer support for patients with type 2 diabetes but could not show 
significant differences between groups in the improvement of the cardiovascular risk factors 
(31). In another study, newly diagnosed type 2 diabetes patients received a 6 hours structured 
group educational intervention, but no significant differences in change in HbA1c, BD or 
LDL-cholesterol between control and intervention group could be shown after 12 months 
neither (32). On the other hand, a recent review assessing the effects of the CCM on diabetes 
patients in the United States found that CCM is effective in improving the health of people 
who have diabetes in primary care. The authors emphasized in their review that no single 
component of the CCM was found to be crucial for improved outcomes, incorporating 
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multiple components together in the same intervention can help facilitate better CCM 
implementation (33). Shojiana et al. concluded in 2004 that multifaceted interventions to 
improve the quality of diabetes care have a greater chance of success than single-faceted 
interventions (34); this finding has been confirmed by several other reviews, addressing 
diabetes care but also other chronic diseases (35, 36). The CCM obviously represents such a 
multifaceted intervention, but surprisingly many trials do not reflect its core elements (12). 
A strength of this trial is that it is a study within a real life setting, reflecting the situation as it 
occurs in most European countries, with small inexperienced practices regarding such 
approaches and a non-existing culture of involving practice nurses in the care. Therefore, our 
results are not only important regarding the disease specific outcomes; they also prove that the 
CCM approach can be implemented with acceptable effort in daily primary care. The CCM 
has shown positive effects in several chronic diseases including diabetes (27, 28, 37-39) but 
evidence regarding implementation in small, often single handed primary care practices as the 
most common type of practice in many European countries is still rare (40).  
This is a pragmatic, cluster randomized controlled trial. Some limitations should be 
acknowledged. First of all, due to the study design it was not possible to blind PCPs and 
practice nurses to group allocation, which might have influenced the results or might have led 
to a more pronounced effect of the intervention. Second, we scheduled follow-up assessments 
one year after baseline assessments and the onset of the implementation of the intervention, 
respectively. We first planned follow-up assessments after two study years to obtain a longer 
implementation period as basis of our analyses. But many PCPs who were allocated to the 
control group also wanted to implement the team approach after the end of the study, so we 
could not let them wait for another year. Finally, cluster effects might influence such trials. 
We have adjusted our power calculation to this but also calculated the intraclass correlation 
coefficient (ICC) of the clinical variables. However, it has to be mentioned that a small cluster 
14 
 
effect only occurred regarding the LDL-cholesterol, interestingly, HbA1c and BP showed no 
clustering at all.  
A chronic care approach according to the CCM and involving practice nurses in diabetes care 
improved the cardiovascular risk profile and is experienced by patients as a better structured 
care. Our study showed that care according to the CCM can be implemented even in small 
primary care practices which still represent the usual structure in most European health care 
systems.   
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Table 1: Baseline characteristics of intervention and control group at cluster (PCPs) and 
individual (type 2 diabetes patients) levels  
 Intervention group 
(n=162) 
Control group 
(n=164) 
PCP factors at baseline   
No of PCPs 15 15 
Mean (SD) age (years) 50.0 (6.9) 51.5 (7.6) 
Men  13 (87) 14 (93) 
Organization of PCPs’ practices:   
   Single handed practice  3 (20) 7 (47) 
   Group practice (>1 PCP)  12 (80) 8 (53) 
Member of a PCP network  10 (67) 7 (47) 
Patient factors at baseline   
Mean (SD) age (years) 65.7 (10.4) 68.3 (10.6) 
Men  88 (54) 99 (60) 
Living together with partner/family (n=314) 125 (79) 121 (78) 
Mean (SD) years of education (n=312) 11.6 (3.2) 11.7 (3.1) 
Smoking (patient reported):   
   Current smoker  22 (14) 14 (9) 
   Former smoker  63 (39) 66 (40) 
   Never smoker  73 (45) 76 (46) 
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   Missing  4 (2) 8 (5) 
Mean (SD) BMI 30.5 (5.3) 30.7 (5.9) 
Antidiabetic therapy:   
   None  4 (2) 8 (5) 
   Only oral  108 (67) 100 (61) 
   Only insulin  11 (7) 15 (9) 
   Combined (insulin and oral)  36 (22) 41 (25) 
   Missing 3 (2) - 
Mean (SD) diabetes duration (years) (n=322) 9.5 (7.4) 10.3 (7.8) 
Mean (SD) no comorbidities  2.5 (1.6) 2.9 (1.5) 
Mean (SD) no of drugs (n=321) 4.6 (2.2) 4.9 ( 2.0) 
Mean (SD) no consultations last year (n=325) 8.3 (6.8) 7.9 (5.2) 
Mean (SD) PHQ summary score (n=302) 5.1 (4.7) 5.3 (4.8) 
Compliance (assessed by PCPs):   
   Very good 47 (29) 62 (38) 
   Rather good 80 (50) 69 (42) 
   Rather and very bad 33 (20) 33 (20) 
   Missing 2 (1) - 
Values are numbers (percentages) unless stated otherwise 
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Table 2: Primary outcome, clinical secondary outcomes and additional characteristics at baseline and follow-up in type 2 diabetes patients per 
allocated group 
 No of participants 
(baseline/follow-up) 
Mean (SD) outcome at 
baseline 
Mean (SD) outcome at 
follow-up 
ICC* Mean difference in 
change between groups 
(95% CI†) 
P 
value‡ 
 Intervention Control Intervention Control Intervention Control    
Primary outcome          
HbA1c (%) 162/147 164/156 7.8 (1.5) 7.6 (1.1) 7.6 (1.2) 7.3 (1.0) <0.001 -0.05 (-0.34 to 0.23) 0.708 
HbA1c (mmol/mol) 162/147 164/156 62 (16) 59 (12) 59 (13) 56 (10) <0.001 -0.60 (-3.72 to 2.52) 0.707 
Secondary outcomes          
Systolic blood pressure (mmHg) 162/145 164/155 140.3 (18.4) 137.8 (16.8) 136.4 (17.5) 137.5 (16.9) 0.019 -3.63 (-7.26 to 0.00) 0.050 
Diastolic blood pressure (mmHg) 162/144 164/155 83.1 (10.4) 78.7 (10.2) 79.6 (9.9) 79.2 (11.2) <0.001 -4.01 (-6.23 to -1.78) <0.001 
LDL-cholesterol (mmol/l) 159/146 164/154 2.8 (1.1) 2.5 (1.1) 2.7 (1.0) 2.6 (1.0) 0.040 -0.21 (-0.39 to -0.02) 0.033 
Additional characteristics          
BMI (kg/m2) 162/146 164/154 30.5 (5.3) 30.7 (5.9) 30.0 (4.9) 30.8 (5.8)  -0.24 (-0.62 to 0.14) 0.213 
HDL-cholesterol (mmol/l) 161/147 164/156 1.2 (0.3) 1.3 (0.4) 1.2 (0.3) 1.3 (0.5)  -0.05 (-0.13 to 0.02) 0.182 
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Total cholesterol /(mmol/l) 162/147 163/156 5.0 (1.2) 4.7 (1.1) 4.9 (1.1) 4.7 (1.1)  -0.08 (-0.28 to 0.13) 0.469 
Waist hip ratio, male|| 87/79 91/84 1.02 (0.08) 1.01 (0.07) 1.01 (0.06) 1.00 (0.06)  0.01 (-0.01 to 0.03) 0.372 
Waist hip ratio, female|| 74/66 62/60 0.92 (0.06) 0.93 (0.09) 0.92 (0.06) 0.94 (0.11)  -0.01 (-0.03 to 0.02) 0.521 
Fasting blood sugar (capillary; 
mmol/l) 
162/145 164/154 8.4 (2.5) 7.7 (2.2) 7.9 (2.0) 7.3 (1.9)  -0.14 (-0.69 to 0.41) 0.612 
*ICC = intraclass correlation coefficient. †Value interpretable in relation to intervention group: Negative value indicates greater negative change and positive value greater 
positive change in intervention group compared to controls. ‡T-test for independent samples. ||Waist circumference (cm)/hip circumference (cm). 
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Table 3: Patient-reported secondary outcome PACIC: scores at baseline and follow-up in type 2 diabetes patients per allocated group 
 
 No of participants 
(baseline/follow-up) 
Mean (SD) outcome at 
baseline 
Mean (SD) outcome at 
follow-up 
P value* 
 Intervention Control Intervention Control Intervention Control  
PACIC        
PACIC: Summary score†) 148/129 142/135 3.1 (0.9) 3.2 (0.8) 3.3 (0.8) 3.2 (1.0) 0.001 
PACIC: Patient activation 153/135 153/139 3.8 (1.1) 3.9 (1.2) 3.9 (1.1) 3.9 (1.2) 0.032 
PACIC Delivery system 148/131 147/140 3.8 (0.9) 3.9 (0.8) 3.9 (0.9) 3.7 (0.9) <0.001 
PACIC Goal setting 147/131 148/137 2.8 (0.9) 2.9 (1.0) 3.1 (1.0) 2.9 (1.1) 0.003 
PACIC Problem solving 149/131 146/135 3.1 (1.3) 3.4 (1.2) 3.4 (1.2) 3.4 (1.2) 0.016 
PACIC Follow-up 146/129 142/137 2.6 (1.0) 2.7 (1.1) 2.7 (1.0) 2.6 (1.2) 0.048 
*Non-parametric Mann Whitney U-test. †For PACIC summary score: 1 missing allowed and replaced by mean value of remaining items. 
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Figure legend 
Figure 1: Flow diagram of recruitment and follow-up of primary care physicians and patients 
 
 
Supplemental Table S1: Multilevel regression analyses to assess the independent effect of the 
intervention on primary and secondary clinical outcomes  
Outcome* Adjusted difference in change 
between groups† 
p-value 
HbA1c‡ -0.11 (95% CI -0.42 to 0.21) 0.511 
Systolic blood pressure§ -4.29 (95% CI -8.19 to -0.39) 0.031 
Diastolic blood pressure§ -3.58 (95% CI -5.96 to -1.19) 0.003 
LDL-cholesterol|| -0.18 (95% CI -0.42 to 0.05) 0.130 
*Difference from baseline to follow-up. †Coefficient for treatment group; negative value indicates greater 
negative change and positive value greater positive change in intervention group compared to controls. 
‡Multivariate controlled for: PCP as cluster level, patient’s sex, patient’s age, smoking status, BMI, number of 
comorbidities, number of visits during study year, total number of drugs, antidiabetic therapy, and change of 
antidiabetic therapy. §Multivariate controlled for PCP as cluster level, patient’s sex, patient’s age, smoking 
status, BMI, number of comorbidities, number of visits during study year, total number of drugs, 
antihypertensive therapy, and change of antihypertensive therapy. ||Multivariate controlled for PCP as cluster 
level, patient’s sex, patient’s age, smoking status, BMI, number of comorbidities, number of visits during study 
year, total number of drugs, lipid-lowering therapy, and change of lipid-lowering therapy.  
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Supplemental Table S2: Characteristics of health care utilization during the year of 
intervention, other patient’s outcomes and medication at baseline and follow-up in type 2 
diabetes patients per allocated group 
 No of participants 
(baseline/follow-up) 
N (%) outcome  
at baseline 
N (%) outcome  
at follow-up 
 Intervention Control Intervention Control Intervention Control 
Health care utilization       
Hospitalizations due to 
hypoglycemic episodes*  
n/a/115 n/a/142   1 (1) 1 (1) 
Hospitalizations due to 
hyperglycemic 
episodes* 
n/a/115 n/a/142   0 (0.0) 3 (2) 
Hospitalizations due to 
cardiovascular episodes* 
n/a/114 n/a/142   8 (7) 6 (4) 
Hospitalizations due to 
other reasons*  
n/a/114 n/a/142   7 (6) 12 (8) 
Other patient’s outcomes      
Number of visits in ge-
neral practice† (m, SD) 
162/143 163/153 8.3 (6.6) 7.9 (5.1) 9.6 (5.6) 8.4 (5.9) 
Compliance (m, SD)‡ 160/145 164/156 1.91 (0.70) 1.84 (0.77) 1.94 (0.79) 1.83 (0.8) 
Severe hypoglycemia 
(≥1 episodes)†§ (m, SD) 
162/146 164/156 13 (8.0) 19 (11.6) 12 (8.2) 8 (5.1) 
Foot status 
(pathological)|| 
161/145 164/155 30 (18.6) 22 (13.4) 26 (17.9) 28 (18.1) 
Peripheral pulse status 
(pathological)¶ 
162/144 164/156 50 (30.9) 47 (28.7) 40 (27.8) 52 (33.3) 
Monofilament test 
(pathological)# 
161/144 151/155 17 (10.6) 25 (16.6) 22 (15.3) 31 (20.0) 
Annual eye exam† 
   pathological 
   non-pathological 
   not conducted 
162/144 161/155  
15 (9.3) 
104 (64.2) 
43 (26.5) 
 
13 (8.1) 
90 (55.9) 
58 (36.0) 
 
15 (10.4) 
110 (76.4) 
19 (13.2) 
 
11 (7.1) 
88 (56.8) 
56 (36.1) 
Medication       
Any antidiabetic therapy 159/147 164/154 155 (97.5) 157 (95.7) 143 (97.3) 146 (94.8) 
   Oral alone** 159/147 164/154 108 (67.9) 100 (61.0) 97 (66.0) 91 (59.1) 
   Insulin alone** 159/147 164/154 11 (6.9) 15 (9.1) 11 (7.5) 14 (9.1) 
   Combined (insulin and 
   oral) ** 
159/147 164/154 36 (22.6) 41 (25.0) 35 (23.8) 41 (26.6) 
Specific antidiabetic 
therapies 
      
   Insulin** 159/147 164/154 47 (29.6) 56 (34.1) 46 (31.3) 55 (35.7) 
   Metformin/Biguanid  159/147 164/154 132 (83.0) 122 (74.4) 124 (84.4) 116 (75.3) 
   Sulfonylurea  159/147 164/153 67 (42.1) 69 (42.1) 65 (44.2) 55 (35.9) 
   Gliptine (DPP-III)  159/147 164/154 20 (12.6) 24 (14.6) 26 (17.7) 31 (20.1) 
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 No of participants 
(baseline/follow-up) 
N (%) outcome  
at baseline 
N (%) outcome  
at follow-up 
 Intervention Control Intervention Control Intervention Control 
   Glitazone  159/147 164/154 8 (5.0) 11 (6.7) 4 (2.7) 14 (9.1) 
   Glinide  159/147 164/154 7 (4.4) 3 (1.8) 3 (2.0) 3 (1.9) 
   Incretin mimetic  159/146 164/154 3 (1.9) 3 (1.8) 2 (1.4) 0 (0) 
   α-Glucosidase 
   inhibitor  
158/147 164/154 4 (2.5) 0 (0) 3 (2.0) 0 (0) 
Any antihypertensive 
therapy** 
159/147 164/154 117 (73.6) 129 (78.7) 113 (76.9) 129 (83.8) 
   Diuretics  159/147 164/153 72 (45.3) 88 (53.7) 79 (53.7) 91 (59.5) 
   Inhibitor of the 
angiotensin converting 
enzyme (ACE-I)  
159/147 164/153 80 (50.3) 76 (46.3) 69 (46.9) 62 (40.5) 
   Beta-blocker  159/147 164/154 46 (28.9) 55 (33.5) 45 (30.6) 53 (34.4) 
   Angiotensin II 
inhibitor (ARB)  
159/147 164/153 25 (15.7) 45 (27.4) 35 (23.8) 53 (34.6) 
   Calcium antagonists  159/147 164/154 33 (20.8) 31 (18.9) 37 (25.2) 34 (22.1) 
   other antihypertensive 
   agents  
159/147 164/154 2 (1.3) 2 (1.2) 8 (5.4) 14 (9.1) 
Any lipid-lowering 
therapy** 
159/147 164/154 80 (50.3) 102 (62.2) 80 (54.4) 96 (62.3) 
   Statin 159/147 164/154 79 (49.7) 101 (61.6) 78 (53.1) 94 (61.0) 
   other lipid-lowering 
   therapy 
159/147 164/154 5 (3.1) 3 (1.8) 4 (2.7) 3 (1.9) 
Any antiplatelet 
therapy** 
159/147 164/154 78 (49.1) 101 (61.6) 81 (55.1) 98 (63.6) 
   Aspirin  159/147 164/154 70 (44.0) 88 (53.7) 71 (48.3) 85 (55.2) 
   Phenprocoumon  159/146 164/154 10 (6.3) 11 (6.7) 9 (6.2) 13 (8.4) 
   Clopidogrel  159/147 164/154 9 (5.7) 8 (4.9) 8 (5.4) 5 (3.2) 
Any antidepressants  159/147 164/154 22 (13.8) 15 (9.1) 26 (17.7) 24 (15.6) 
Number of drugs total 
(m, SD) 
157/145 164/150 4.6 (2.2) 4.9 (2.2) 5.1 (2.2) 5.3 (2.0) 
*At least 1 hospitalization within the last 12 months. †Within the last 12 months. ‡Compliance assessed by GP: 
1=very good, 2=rather good, 3=rather bad, 4=very bad. §Clinical symptoms and/or hospitalizations/need for 
action. ||Pathological if either osteoarthropathy, mycosis or ulcerations. ¶Pathological if 1 of 4 arteries non-
palpable (A. tibialis posterior, a. dorsalis pedis), bilateral. #According to Semmes-Weinstein. **1 or more drugs 
possible. 
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